Pfizer Czech Republic's total assets reached CZK 2,549 mil at the end of 2017, up 24.3% compared to the previous year.
Current assets amounted to CZK 2,234 mil, or 87.6% of total assets while cash stood at CZK 8.88 mil at the end of 2017.
By contrast, total debt reached CZK 338 mil at the year-end, or 13.2% of total assets, while the firm's equity amounted to CZK 1,355 mil. As a result, net debt stood at CZK 329 mil at the end of 2017 and accounted for 24.2% of equity.
Net debt against equity is up 32.7 pp from five years ago (-8.43%). The ratio against EBITDA increased from -1.32x seen in 2012 to 2.10x.
The company’s cost of funding amounted to 3.65% in 2017, up 0.005 pp compared to the average over the last 5 years.
You can see all the company’s data at Pfizer Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
